MannKind (NASDAQ:MNKD – Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect MannKind to post earnings of $0.03 per share and revenue of $74.99 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
MannKind Price Performance
MNKD opened at $5.77 on Monday. MannKind has a 12 month low of $3.47 and a 12 month high of $7.63. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of 82.36 and a beta of 1.28. The business has a fifty day moving average price of $6.06 and a 200 day moving average price of $6.28.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on MNKD shares. Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $7.00 to $10.00 in a report on Thursday, December 19th. Wedbush started coverage on MannKind in a report on Monday, February 10th. They set an “outperform” rating and a $11.00 target price on the stock. Wells Fargo & Company assumed coverage on MannKind in a research report on Friday, December 20th. They issued an “overweight” rating and a $9.00 target price on the stock. Finally, StockNews.com lowered MannKind from a “buy” rating to a “hold” rating in a research report on Saturday, December 7th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $9.21.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Featured Articles
- Five stocks we like better than MannKind
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- What is the Hang Seng index?
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
